Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Chugai Pharmaceutical Co., Ltd.    4519   JP3519400000


SummaryAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai and NTT DATA Complete Demonstration of AI-based Clinical Trial Efficiency Solution

share with twitter share with LinkedIn share with facebook
09/10/2020 | 09:36am EDT

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) and NTT DATA Corporation (TOKYO: 9613) have conducted a demonstration test of a solution for improving the efficiency of clinical trial-related document preparation using AI technology from January to June, 2020.

Clinical trial operations require the creation of a variety of documents and procedures from planning to implementation and application for drug approval. NTT DATA has been developing a solution based on the concept of improving the process efficiency of documentation, for example, by automatically creating clinical trial-related documents from a clinical trial protocol1). In this demonstration, Chugai and NTT DATA are collaborating by conducting concept verification, evaluating the usefulness of this solution and identifying future system issues.

Based on the results of this demonstration, NTT DATA aims to provide commercial services of this solution in FY2021. Furthermore, based on the cooperative relationship between the two companies obtained through this demonstration, we will collaborate and accelerate our efforts toward digital transformation of clinical development operations

New drug development is a process that involves research, collection and analysis of clinical data in clinical trials, and evaluation of efficacy and safety. It usually takes about 9 to 17 years on average to launch a new drug2). Both pharmaceutical companies and medical institutions participating in clinical studies have expended so much effort to ensure the quality of clinical trial activities and data. In addition, efficient development of high-quality clinical trial-related documents is a common challenge among pharmaceutical companies.

NTT DATA is developing a cross-pharmaceutical company/clinical site total solution platform for clinical trials to connect a wide range of clinical trial processes through the most advanced IT technology to help accelerate new drug development.

Under the goal of optimization of all value chains, one of the basic strategies of CHUGAI DIGITAL VISION 20303), Chugai aims at further acceleration of clinical trial processes. Chugai supports NTT DATA's initiative and conducted the demonstration test jointly with NTT DATA to develop a new solution using AI technology, leveraging Chugai's extensive experience.

The solution, as one of total solution platforms for clinical trials, allow sequential and comprehensive generation of various clinical trial-related documents (such as informed consent form for patients, statistical analysis plan, case report form to enter patients' clinical trial data, and clinical study report summarizing the clinical trial results), using data from the protocol as input information, through AI technology, as well as technology components such as ontology4) and semantics5).


To identify requirements for solving the challenges in efficient development of high-quality clinical trial-related document, aiming at digital transformation in clinical development activities.


To validate the usefulness of the concept to sequentially and automatically generate clinical trial-related documents required for clinical development activities, and to evaluate technology components for realization.

Specifically, we compared time required for the preparation of the informed consent form and the case report form (blank) from Chugai's protocol as input information, using the prototype of the solution, with the actual time spent for the comparable activities in the past.


From January to June 2020

Validation Results

The usefulness of this solution's concept was successfully validated identifying tasks ahead. The validation results of the effectiveness are as follows;

Reduction in time required for the preparation of the informed consent form and the case report form (blank) was 61% and 40% on average, respectively.

In both documents, successful automatic generation was demonstrated mostly as planned. In certain parts of the documents where automatic generation was expected to be difficult, reduction in time was proven to be small as predicted.

The case report form (blank) had to be corrected manually as appropriate after the automatic generation, which was one of the factors that reduced the reduction effect rate.

Leveraging the technology components validated in the demonstration test, NTT DATA will expand the applicable clinical trial-related documents, provide a standardized template, and implement suggest functions with AI6) and multiple language support functions sequentially in the solution. In addition to the solution, NTT DATA will seek to provide a total solution platform for clinical trials, including the solution for supporting collection and structuring of clinical data. Chugai and NTT DATA are working together toward the digital transformation of clinical development operations and contributing to the creation of a new framework for more efficient drug development.

Efficient development of high-quality clinical trial-related documents is a common challenge among pharmaceutical companies. We are very pleased that Chugai's expertise and experience accumulated in clinical development may contribute to the initiative to accelerate new drug development by building a shared clinical trial platform for pharmaceutical companies and medical institutions with the use of AI technology. Under CHUGAI DIGITAL VISION 2030, Chugai has set its goal to be a top innovator that will provide society-changing healthcare solutions by transforming our business. We will continue to actively work with external partners to lead innovation in the healthcare industry.

Satoko Shisai, Chugai's Vice President, Head of Digital & IT Supervisory Division

We sincerely appreciate that we have successfully completed the demonstration test with Chugai aiming toward digital transformation in clinical development activities. We hope that our innovative solutions developed through our collaboration will resolve the common challenge in clinical development activities in the pharmaceutical industry and help build a foundation to ensure the swift delivery of new drugs to patients. NTT DATA is committed to realizing a healthy longevity society and secure and safe living, as well as contributing to the creation of the future society with customers, using advanced IT technology.

Hidenori Chihara, NTT DATA's Executive Vice President, Head of Public Sector 2

About Chugai

Chugai Pharmaceutical is one of Japan's leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which will satisfy unmet medical needs.


NTT DATA - a part of NTT Group - is a trusted global innovator of IT and business services headquartered in Tokyo.

We help clients transform through consulting, industry solutions, business process services, IT modernization and managed services. NTT DATA enables clients, as well as society, to move confidently into the digital future. We are committed to our clients' long-term success and combine global reach with local client attention to serve them in over 50 countries.


Tel: +81-3-3273-0881

Email: pr@chugai-pharm.co.jp

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD. -0.53% 4715 End-of-day quote.40.33%
NIPPON TELEGRAPH AND TELEPHONE CORPORATION -3.61% 2150 End-of-day quote.-22.02%
NTT DATA CORPORATION -5.69% 1342 End-of-day quote.-8.52%
ROCHE HOLDING AG 0.02% 315.2 Delayed Quote.0.37%
share with twitter share with LinkedIn share with facebook
09/28CHUGAI PHARMACEUTICAL : Obtains Approval for Additional Indication of Tecentriq ..
09/10Chugai and Takeda to Join a Clinical Collaboration for Global Phase III Studi..
09/10Chugai and NTT DATA Complete Demonstration of AI-based Clinical Trial Efficie..
09/10CHUGAI PHARMACEUTICAL : New Data of Chugai's Enspryng (Satralizumab) on Risk and..
09/02CHUGAI PHARMACEUTICAL : Introduces LINE WORKS by WORKS MOBILE Japan for 2,400 Em..
08/27CHUGAI PHARMACEUTICAL : Launches Enspryng Subcutaneous Injection 120 mg Syringe,..
08/27CHUGAI PHARMACEUTICAL CO. LTD. : - Non-Clinical Research Results of Chugai's Swi..
08/26CHUGAI PHARMACEUTICAL : Selected as Digital Transformation Stock 2020
08/24CHUGAI PHARMACEUTICAL : Obtains Approval for Additional Indication of Kadcyla fo..
08/20ALERT : New purchases in the MarketScreener Asia portfolio
More news
Sales 2020 766 B 7 255 M 7 255 M
Net income 2020 213 B 2 012 M 2 012 M
Net cash 2020 415 B 3 934 M 3 934 M
P/E ratio 2020 35,8x
Yield 2020 1,13%
Capitalization 7 750 B 73 483 M 73 389 M
EV / Sales 2020 9,57x
EV / Sales 2021 8,66x
Nbr of Employees 7 394
Free-Float 37,7%
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 4 956,42 JPY
Last Close Price 4 715,00 JPY
Spread / Highest target 48,5%
Spread / Average Target 5,12%
Spread / Lowest Target -25,8%
EPS Revisions
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.06%391 975
ROCHE HOLDING AG0.37%293 803
MERCK & CO., INC.-8.80%209 801
PFIZER, INC.-7.68%203 937
NOVARTIS AG-13.05%191 928